Profile Name | BRAF G464V KRAS G13D |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | BRAF G464V KRAS G13D | breast cancer | sensitive | Gedatolisib | Preclinical | Actionable | In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276). | 17314276 21325073 | BRAF G464V KRAS G13D | breast cancer | sensitive | Encorafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a breast cancer cell line harboring BRAF G464V and KRAS G13D in culture (PMID: 29903896). | 29903896 | BRAF G464V KRAS G13D | breast cancer | sensitive | Regorafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960). | 21170960 | BRAF G464V KRAS G13D | breast cancer | predicted - resistant | Trametinib + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a breast cancer cell line harboring BRAF G464V and KRAS G13D in culture (PMID: 29903896). | 29903896 | BRAF G464V KRAS G13D | breast cancer | decreased response | CH5132799 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396). | 21558396 | BRAF G464V KRAS G13D | breast cancer | no benefit | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a breast cancer cell line harboring BRAF G464V and KRAS G13D in culture (PMID: 29903896). | 29903896 | BRAF G464V KRAS G13D | triple-receptor negative breast cancer | sensitive | DHM25 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138). | 26237138 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|